SIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel

Stock News

06/01

SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.

Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.

The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.

This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1162893860"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162893860\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162893860?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162893860","market":"sg","top_or_hot":-1,"title":"SIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel","media":"Stock News","content":"<p>SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.<br><br>Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.<br><br>The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.<br><br>This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA Secures Exclusive Rights to Promote Pemecitinib Gel\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 19:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.<br><br>Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.<br><br>The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.<br><br>This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1162893860","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162893860","pubTimestamp":1780314017,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.Under...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","02096":"先声药业","BK1191":"制药","BK1515":"抗疫概念","09939":"开拓药业-B","BK1161":"生物科技","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"translate_title":"先声药业获得培美替尼凝胶独家推广权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02096":1},"content_text":"SIMCERE PHARMA (ASX: 02096) has announced the signing of an exclusive promotion services agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. (Puqi Pharma) for the Pemecitinib Gel.Under the terms of the agreement, the group has secured exclusive rights to promote Pemecitinib Gel for all dermatological indications in mainland China, Hong Kong, and Macau.The New Drug Application for the Pemecitinib Gel, targeting atopic dermatitis in adults and adolescents, has been accepted for review by the Center for Drug Evaluation of the National Medical Products Administration.This collaboration is expected to strengthen the group's product portfolio in the autoimmune disease sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}